Replies to post #222109 on Biotech Values

[jq1234]

How would that affect response rate in this case?

Discontinuation rate due to TRAEs very low - 2 out of 41 treated patients even though only 38 used for efficacy - even lower than nivolumab alone in the background, how could dealing with AEs differently really affect response rate? Maybe academic centers enrolled patients with different baseline characteristics from other sites? This is generally true in all clinical trials, once you expand to larger number of sites, patients enrolled become much more diverse.